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BioinformaticsThis study focused on identifying the conserved epitopes in a single subtype A (H3N2)—as candidates for vaccine
targets. We identiﬁed a total of 32 conserved epitopes in four viral proteins [22 HA, 4PB1, 3 NA, 3 NP]. Evaluation
of conserved epitopes in coverage during 1968–2010 revealed that (1) 12 HA conserved epitopes were highly
present in the circulating viruses; (2) the remaining 10 HA conserved epitopes appeared with lower percentage
but a signiﬁcantly increasing trend after 1989 [pb0.001]; and (3) the conserved epitopes in NA, NP and PB1 are
also highly frequent inwild-type viruses. These conserved epitopes also covered an extremely highpercentage of
the 16 vaccine strains during the 42 year period. The identiﬁcation of highly conserved epitopes using our
approach can also be applied to develop broad-spectrum vaccines.
© 2012 Elsevier Inc. All rights reserved.1. Introduction
Inﬂuenza A viruses are negative-sense RNA viruses that possess a
segmented genome of eight single-stranded RNA segments and encode
eleven proteins. These viruses undergo genetic drifts and shifts due to
error-prone replication of viral genomes and reassortment of viral
gene segments [1]. Consequently, inﬂuenza A viruses escape that
immune system of their hosts resulting in inﬂuenza epidemics and
pandemics.
Antigenic drift is the continuous process of genetic and antigenic
changes that occur through point mutations. On average it occurs
every two to eight years in response to selection pressure to evade
human immunity [2]. The antigenic distance between ﬂu strains is
increasing with time by the drift. To address this, inﬂuenza vaccines
are reviewed annually to ensure protection is maintained despite the
emergence of drift variants [3]. Moreover, the reassortment of inﬂuenza
A viruses leads to antigenetic and genetic variabilities and dynamic
interactions of viral gene segments of inﬂuenza viruses derived from
different species of hosts. In the past century, inﬂuenza viruses had
caused several major pandemics, namely the 1918 Spanish pandemic
(H1N1), the 1957 Asian pandemic (H2N2) and the 1968 Hong Kong
pandemic (H3N2) [4]. These pandemic viruses obtained novel HA, NA
and PB1 gene segments either through direct animal (poultry)-to-Synthetic Biology, Institute of
, No. 155, Sec. 2, Li-Nong St.,
rights reserved.human transmission or through mixing of human inﬂuenza A and
animal inﬂuenza A virus genes to create a new human inﬂuenza A
subtype virus under a process called genetic reassortment, resulting in
antigenic shift, phenotypic change and spread among human popu-
lations without prior immunity [5–7].
In facing such challenges and needs against the changing compo-
nents of inﬂuenza vaccine, one possible approach of developing a uni-
versal inﬂuenza vaccine is to design a vaccine using the conserved
immunogenic regions in the viral proteins to protect human population
against inﬂuenza viruses. The universal inﬂuenza vaccines currently
under development were designed mainly based on the highly con-
served external domain of the inﬂuenzamatrix 2 (M2) protein and con-
served epitopes from the inﬂuenza NP, matrix 1 (M1), and HA proteins.
In 2007, a computational prediction of HLA restricted T-cell epitope
sequences in the conserved regions of inﬂuenza A virus proteins was
performed [8]. However, those predicted epitopes still need to be
veriﬁed by further experiments [9]. In 2010, one study demonstrated
a hemagglutinin subunit 2 protein (HA2)-based synthetic peptide
vaccine that provides protection in mice against inﬂuenza viruses of
the structurally divergent subtypes H3N2, H1N1, and H5N1 [10].
Due to the antigenic variability of inﬂuenza A viruses among differ-
ent subtypes, only few viral epitopes have been shown to induce host
immune response. A highly conserved domain of the M2 protein
(M2e) in almost all inﬂuenza A viruses was identiﬁed [11]. Recently, it
has been reported that there is only one HA conserved epitope in inﬂu-
enza A viruses recognized by antibodies [12].
Practically, a universal vaccinemight restrict the ability of protection
against particular subtypes of inﬂuenza A viruses. A universal antibody
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but the antibody failed to neutralize the viruses of H3 and H7 [13].
Therefore, Sui et al. argued that a cocktail vaccine comprising broad-
spectrum antibodies of different subtypes could provide broad protec-
tion against all seasonal and pandemic inﬂuenza A viruses.
Several recent studies have used bioinformatics approach to identify
conserved domains across inﬂuenza A viral strains. One study discov-
ered 19 universal conserved functional motifs and accessible regions
for functional mapping and annotation [14]. Another study reported
motifs within the HA protein and correlated them with a high number
of potential post-translational modiﬁcation sites that overlap antigenic
and receptor binding sites [15,16]. A third study performed phylogenic
analysis and addressed the evolution of inﬂuenza A viral segments [16].
However, the analysis of protein and epitope sequences between inﬂu-
enza A/H3N2 viruses and vaccine strains remains to be elucidated.
Therefore, this study focused on identifying conserved epitopes in a
single subtype rather than in all subtypes. We conducted a sequence-
based analysis of available inﬂuenza B-cell and T-cell epitopes for
human aswell asmeasured sequence conservations of epitopes in inﬂu-
enza A/H3N2 viruses, the most rapid changing subtype, to provide
the information with statistical methods for the candidates of broad-
spectrum vaccine. The aims of this study were: (1) to investigate the
viral diversity in inﬂuenza A/H3N2 viruses for ﬁnding representative
viral clusters, (2) to identify the conserved epitopes in all viral proteins
and (3) to evaluate the coverage of the conserved epitopes among
various inﬂuenza strains.
2. Results
2.1. Distribution of clusters in different inﬂuenza proteins
Peptide sequences of each of all the non-identical and full-length
amino acids in the 11 viral protein sequences of inﬂuenza A/H3N2
viruseswere retrieved directly from theNCBI Inﬂuenza Resources Data-
base [17]. A total of 7690 protein sequences were retrieved (Table 1).
The k-means clustering algorithm was used to group viral amino
acid sequences into clusters. PB1-F2, NP and M1formed 15 clusters;
NS1 formed 10 clusters; NA and M2 formed 6 clusters; PB2, PB1, PA,
HA and NS2 datasets formed 5 clusters (Table 1). A consensus sequence
was then generated as a representative sequence for each cluster.
2.2. Epitope sequences conserved in inﬂuenza A/H3N2 viruses
After performing the 5-fold cross-validation (with t-test) between
the training and testing sequence data sets, we identiﬁed a total of 32
conserved epitopes (Table 2). These epitopes were located in only four
of the proteins of inﬂuenza A/H3N2: HA (22 epitopes), NA (3 epitopes),
PB1 (4 epitopes) and NP (3 epitopes). In general, more epitopes
were found in the structural HA and NA proteins than in viral internalTable 1
The number of inﬂuenza A/H3N2 virus protein sequences used in this study and the
number of representative clusters identiﬁed by k-means clustering.
Protein Number of sequences (%) Number of clusters
NA 1789 (23.26) 6
HA 1619 (21.1) 5
PA 721 (9.38) 5
PB1 695 (9.0) 5
PB2 689 (9.0) 5
NS1 628 (8.2) 10
NP 432 (5.6) 15
PB1-F2 426 (5.5) 15
M2 346 (4.5) 6
M1 199 (2.6) 15
NS2 146 (1.9) 5
Total 7690 (100) 92proteins, using currently available epitope data sources. From an immu-
nological perspective, the conserved epitopes involved 31T-cell epitopes
and only one B-cell epitope (see Supplementary data 1–4). In addition,
most of the identiﬁed T-cell epitopes were CD4+ T-cell epitopes
(26/32, 81.3%), including 21 HA (20.6%); 3 NA; 1PB1, and 1 NP. On
the other hand, only 5 conserved CD8+ T-cell epitopes were identiﬁed
[3 PB1 (30.00%), 2 NP, 1 NA].
2.3. Conserved epitopes showed high identities among ﬂu vaccine strains
during 1968–2010
For practical concerns of vaccine development, we evaluated the
coverage and sequence identities of our identiﬁed conserved epitopes
against the conserved epitopes among various inﬂuenza vaccine strains.
Figs. 1–2 show that these conserved epitopes had over 96% sequence
identities to the sequence of ﬂu vaccine strains during 1968–2010
[HA in 16 strains: 96–100%±0.00–4.13%, NA in 12 strains: 99–
100%±0.00–2.34%, NP in 8 strains: 99–100%±0.00–2.21% and PB1 in
4 strains: 100%±0.00%]. These results revealed the feasibility of prepar-
ing a broad-spectrum vaccine, using the amino acid sequence informa-
tion from the conserved epitopes.
2.4. Conserved epitopes existed in inﬂuenza A/H3N2 viruses during
1968–2010
To ﬁnd out whether the identiﬁed conserved epitopes were present
in circulated H3N2 strains over the past years, we calculated the
percentages of conserved epitopes existing in all H3N2 viruses. The con-
served epitopes during 1968–2010 could be classiﬁed into three types,
including: (1) 12 frequently present HA conserved epitopes (8 in HA1
and 4 in HA2), with mean±standard deviation (S.D.) of 93–98±
5.37–16.94%, (2) 10 rarely present the remaining 10 HA conserved epi-
topes (8 in HA1 and 2 in HA2) [mean±S.D.: 47–86%±29.45%–47.90%],
with a signiﬁcant increase in percentage of the presence in wild-type
viruses after 1989 than those before 1988 [after 1989 vs. before 1988:
94%±14.1 vs. 34%±45.0, pb0.001; HA2: 93±18.4% vs. 63±45.9%,
pb0.001]; and (3) all the 4 NA, 3 NP and 3PB1 conserved T-cell epitopes
also displayed with high percentages in all the available sequences of
the wild-type viruses during the studied 42 years [95–97%±3.09–
8.69%, 99–100% ±0.54–2.09%, 100% ±0.12–0.99%] (Figs. 3–4).
3. Discussion and conclusion
There is a need to develop a universal vaccine against all types of
inﬂuenza virus to provide long-lasting and cross-strain protection.
By identifying the conserved regions in the proteins of the inﬂuenza
virus without antigenic variability by strain or over time, we provide
candidates for the development of epitope-based universal inﬂuenza
vaccine. In this studywe carried out computational analysis with statis-
tical inference to identify 32 conserved epitopes in inﬂuenza A/H3N2
viral proteins. The conserved epitopes have high sequence identities
(>99%) in most of ﬂu vaccine strains during 1957–2009 and high
conservation in inﬂuenza viruses over the past 33 years (1968–2010).
Further results indicated that conserved epitopes had over 96%
sequence identities in ﬂu vaccine strains, and that these epitopes
existed frequently (96–100%) in wild-type vaccines during 1989–2010.
3.1. Feasibility of epitope-based vaccine developed in the future
Recent literature reported that the antibody CR8020 has broad
neutralizing activity against most of the group 2 inﬂuenza viruses,
including H3N2 and H7N7 [18]. The antibody recognizes the conserved
epitope (GIFGAIAGFIENGWEGMVDGWYGFR, 346–371 aa) located in
the HA2 domain (346–566 aa)—a conserved region in the HA protein
that plays a role in the fusion activity of inﬂuenza infection [19].
Furthermore, previous studies indicated that HA2-based synthetic
Table 2
The number of inﬂuenza A/H3N2 epitopes identiﬁed in 11 viral proteins.
Protein Epitope
B cell CD4+ T cell CD8+ T cell Overall
Conserved Total Percentage Conserved Total Percentage Conserved Total Percentage Conserved Total Percentage
HA 1 23 4.35 21 102 20.59 0 5 0.00 22 130 16.92
PB1 0 5 0.00 1 7 14.29 3 10 30.00 4 22 18.18
NP 0 3 0.00 1 62 1.61 2 33 6.06 3 98 3.06
NA 0 6 0.00 3 78 3.85 0 1 0.00 3 85 3.53
M1 0 4 0.00 0 70 0.00 0 15 0.00 0 89 0.00
PB2 0 1 0.00 0 2 0.00 0 3 0.00 0 6 0.00
PB1-F2 0 3 0.00 0 0 0.00 0 0 0.00 0 3 0.00
PA 0 2 0.00 0 0 0.00 0 1 0.00 0 3 0.00
M2 0 4 0.00 0 0 0.00 0 3 0.00 0 7 0.00
NS1 0 2 0.00 0 5 0.00 0 5 0.00 0 12 0.00
NS2 0 1 0.00 0 2 0.00 0 0 0.00 0 3 0.00
Total 1 54 1.85 26 328 7.93 5 76 6.58 32 458 6.99
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including H3N2 viruses [10,20]. HA2-speciﬁc antibodies can inhibit
the fusion activity of inﬂuenza HA proteins to reduce the ability of
viral replication [21].
As mentioned above, previous studies showed that the immune
responses induced byHA2-based synthetic peptide vaccine can prevent
the inﬂuenza infection. The HA conserved epitopes (IEDB ID: 97341,
346–363 aa) located in the HA2 domains and the conserved epitopes
could be responsible for the induction of antigenicity against inﬂuenza
A/H3N2 viruses (see Supplementary data 5). Furthermore, conserva-
tions of other HA conserved epitopes are greater than those of HA con-
served epitopes. It suggested that there were more potential epitopes
that could be candidates for the universal vaccine.
The NA molecule is another major protein and antigen on the viral
surface and is involved in the release of the viral particles from infected
host cells. The NA gene has a high nucleotide substitution rate, resulting
in antigenic drift [22]. There are several ways to produce protection
against inﬂuenza viruses, one of them is to raise antibodies against HA
protein, hence block the binding of viruses to sialic acids on the host
cell and preventing viral infection. Antibodies binding to NA stop the re-
lease of viruses from infected cells and limit the spread of the virus [23].
The list of NA conserved epitopes can be used to induce antibodies
against inﬂuenza viruses to limit its spread. Furthermore, antibodies
will only bind speciﬁcally to the functional regions to prevent viral
release and allow patients to recover from infection.
Viral genomic RNAs, polymerase and NP protein are incorporated
into virions as ribonucleoprotein complexes. Although NP is an internalFig. 1. The percentage of inﬂuenza A/H3N2 viruses containing HA conserved epitopes durin
methods.protein located inside the virions, studies have shown that NPmay con-
tribute to protect immunity in animalmodel against diverse subtypes of
inﬂuenza viruses through its ability to stimulate cellular immunity
[24,25]. Many vaccination strategies have used the NP protein as an
antigen to induce immune responses since it is well-conserved across
inﬂuenza virus subtypes [26]. We identiﬁed three NP conserved
epitopes including one CD4+ and two CD8+ T-cell epitopes with
high sequence conservation. Therefore, an epitope-based vaccine devel-
oped from NP protein or viral antigens in combination with NP protein
may provide higher protective efﬁcacy against inﬂuenza viruses and be
considered as a candidate for the universal vaccine design.
The PB1 protein is a subunit of the polymerase complex in inﬂuenza
viruses. Sequence comparisons have revealed that the PB1 is the most
conserved segment in human strains [14]. Due to its high sequence
conservation and essentiality, PB1 has recently been thought as an
ideal target for drug binding [27]. An earlier report suggested that PB1
can be considered for vaccine development since PB1 had contributed
the highest number of epitopes for both class I- and class II-restricted
responses in that study [28]. The PB1 conserved epitopes (IEDB ID:
97653) in our results are almost identical, we showed that the epitopes
may be grouped into the same clusters to show similar properties. The
PB1 conserved epitopes that showed less than 100% conservation may
provide more choices for universal vaccine design. However, unlike
HAor NA surface poteins, PB1may not be the primary target recognized
by the host immune system. Another application is to use the conserved
epitopes for the design of drug target because of the biological impor-
tance of the conserved regions.g the 1968–2010 period. The percentage was calculated as described in Materials and
Fig. 2. The percentage of inﬂuenza A/H3N2 viruses containing NA (panel A), NP (panel B), and PB1 (panel C) conserved epitopes during the 1968–2010 period. The percentage was
calculated as described in Materials and methods.
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design
Antibodies induced by B cells play a key role in protection against
inﬂuenza infection in vivo [29]. Therefore, B-cell epitopes are an impor-
tant component in the design of traditional vaccines against inﬂuenza
A/H3N2 viruses. Unlike the abundance of T-cell epitopes, there was
only one B-cell epitope identiﬁed in our study, and it is located in the
HA2 domain. This conserved epitopemay also be considered as a candi-
date for the universal vaccine.
During inﬂuenza virus infection, cellular immunity induced by
CD4+ and CD8+ T cells plays an important role to eliminate virus-
infected cells. In this study, 26 CD4+ and 5 CD8+ T-cell conserved
epitopes were found in HA, NA, NP and PB1 proteins. Previous studiesFig. 3. Sequence identities of HA conserved epitopes among inﬂuenza vaccine strains. The val
strains because sequences of those vaccine strainswere not full-length. Average: A of epitope coshowed that T-cell response can reduce the severity of viral infection
in human [30,31], and the memory T-cell immunity can protect the
human population against inﬂuenza viruses [32]. Therefore, the con-
served T-cell epitopes may be used as vaccine candidates and
protect humans from serious viral infection.
The M2e epitope identiﬁed in previous studies showed cross-
reactivity against various strains and different subtypes of inﬂuenza
viruses [11,33]. However, the M2e epitope is not a conserved epitope
deﬁned by this study. A possible explanation is that the different levels
of genomic diversity of inﬂuenza A/H3N2 viruses were observed at dif-
ferent times over different geological regions [34,35]. For this reason,
the heterosubtypic epitope might not provide maximum immunologi-
cal protection against inﬂuenza viruses that diverged quickly. On the
other hand, our current analysis did not consider the cross-reactivityues were calculated by using the BLAST tool. NA: The epitope is not found in the vaccine
nservations inﬂu vaccines. SD: Standard deviation of epitope conservations inﬂu vaccines.
Fig. 4. Sequence identities of NA (panel A), NP (panel B), and PB1 (panel C) conserved epitopes among inﬂuenza vaccine strains. The values were calculated by using the BLAST tool.
NA: The epitope is not found in the vaccine strains because sequences of those vaccine strains were not full-length. Average: A of epitope conservations in ﬂu vaccines. SD: Standard
deviation of epitope conservations in ﬂu vaccines.
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such analysis.
3.3. High population coverage of inﬂuenza vaccines
A critical thing for T-cell epitope-based vaccine strategy is to identify
and select T-cell epitopes that bind to several alleles of HLA supertypes
to reach maximal population coverage [36]. Here, the HLA types of
conserved epitopes in this study include A3, A28, B7, B8, B27, DR1,
DRA, DRB1 and DRB5 (see Supplementary data 6–10). High population
coverage can be achieved in most prominent ethnicities by focusing on
only three major HLA class I types: A1, A3 and B7 [37,38]. In previous
studies, HLA class I A2, A3 and B7 supertype-restricted epitopes
conserved among different inﬂuenza subtypes were identiﬁed, and it
can be of relevance for the development of a potential type-restricted,
T-cell epitope-based vaccine [8,28,39,40].
3.4. Can these conserved epitopes also be found in avian and/or swine
H3N2 isolates or in inﬂuenza A/H1N1?
There is one HA conserved epitope (IEDB ID: 97341, GIFGAIAGFIE-
NGWEGMV, 346–363 aa) very similar to the avian epitope reported in
IEDB database (IEDB ID: 20838, GLFGAIAGFIE, 345–355 aa). The epitopesequence of the hemagglutinin of avian inﬂuenza A virus H1N1 at amino
acid residues 345–355 shares about 90% protein sequence identity with
human inﬂuenza A/H3N2. This is the only epitope that was found to be
common to avian and human inﬂuenza isolates, while there is no con-
served epitope found between human and swine inﬂuenza isolates.
A total of 32 conserved epitopes were identiﬁed in HA, NA, PB1 and
NP proteins of human inﬂuenza A/H3N2. Sequence comparison of
the conserved epitopes against the strains H1N1, H5N1 and H9N2
showed that 22 HA and 3 NA conserved epitopes were unique to inﬂu-
enza A/H3N2. For NP epitopes, two of three were found in both A/H3N2
andA/H5N1 (IEDB ID: 27126, 225–233 aa; IEDB ID: 27283, 265–273 aa).
For PB1 epitopes, two were found to be common in both A/H3N2 and
A/H5N1 (IEDB ID: 97653, 402–419 aa; IEDB ID: 97682, 21–38 aa),
and two epitopes were found to be common in A/H3N2, A/H1N1, and
A/H9N2 (IEDB ID: 4177, 349–357aa; IEDB ID: 21574, 540–548 aa).
4. Conclusion
This study was designed to identify the candidates of highly con-
served epitopes of inﬂuenza A/H3N2 viruses for the broad-spectrum
epitope-based vaccine design. Conserved epitopes were identiﬁed in
several proteins including: HA, NA, NP and PB1 proteins. We proposed
that the conserved epitopes identiﬁed in this study be considered as
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have suggested that epitopes with robust conserved patterns in inﬂuen-
za A/H3N2 viral proteins are promising functional candidates for broad-
spectrum epitope-based vaccine design.
4.1. Future efforts
Wehave computationally identiﬁed conserved epitopes of inﬂuenza
A/H3N2 viruses with the support of statistical tests. Developing broad-
spectrum vaccines against inﬂuenza viruses requires a fast and robust
strategy and procedure. For preventing or controlling ﬂu outbreaks,
the technology of producing abundant epitope-based vaccines can be
achievedbyusing synthetic epitopepeptides. Finally,we need to under-
stand and advance our knowledge on inﬂuenza viruses and provide a
more efﬁcient preventive method to protect humans from the threats
of inﬂuenza viruses.
5. Materials and methods
5.1. Approach overview
The main objective of this study is to identify epitopes that are
highly conserved over long periods of time within existing inﬂuenza
A/H3N2 viruses. Fig. 5 shows an overall study design involving a
six-step process employed in this study. Before calculating the con-
servations of epitope sequences, we considered that some highly
similar sequences in inﬂuenza viruses could affect the calculation of
epitope conservations. Therefore, we grouped the viruses that share
similar viral protein sequences by clustering analysis and generated
the consensus sequences of each cluster. Epitope conservations were
then estimated using those consensus sequences. In addition, to
evaluate the statistical signiﬁcance of epitope conservations, we calcu-
lated the means and standard errors of conservations by randomFig. 5. The workﬂow for identifying conserved epitopes in inﬂuenza A/H3N2 viruses.
1: The 11non-redundant full-length protein segments of human inﬂuenzaA/H3N2 viruses
were retrieved. 2: The process involves 500 runs of random sampling with a ﬁve-fold
cross-validation to obtain two subsets in each process. 3: Sequence alignment was per-
formed by the MUSCLE software. 4: Sequence distances were calculated by pairwise com-
parison of the sequence differences with Poisson correction model. 5: The cluster size was
obtained by optimum average silhouette width. 6: The human-related T-cell and B-cell
linear epitope sequences with positive responses from the IEDB were collected. 7: The
consensus sequence, or the representative sequence, in each cluster was determined by
a simple majority rule consensus method. 8: The percentage of epitope conservation
was calculated by dividing the number of epitopes that are identical to consensus
sequences by the total number of consensus sequences and then multiplying by 100. 9:
T-testwas used to test the conservations of two subsets and to determinewhether conser-
vations of subsets ≥99%.sampling for each subset. Epitopes conserved in up to 99% inﬂuenza
A/H3N2 viruses were deﬁned as conserved epitopes. Furthermore, to
evaluate the coverage among various inﬂuenza strains, we investigated
whether conserved epitopes existed in the past years andwhether they
showed high sequence identities in ﬂu vaccine strains.
5.2. Data collection of inﬂuenza A/H3N2 protein sequences and epitope
sequences
The available 11 protein sequences of human inﬂuenza A/H3N2
viruses, namely PB2, PB1, PB1-F2, PA, HA, NP, NA, M1, M2, NS1 and
NS2, were downloaded from the National Center for Biotechnology
Information (NCBI) Inﬂuenza Virus Resource [17] on March, 2011.
Only the full-length protein sequences were selected and identical
sequences were removed.
We selected inﬂuenza B- and T-cell epitope sequences from Immune
Epitope Database (IEDB) [41]. These epitopes were able to induce
immunity in experimental tests (query options in IEDB: –linear se-
quences of epitopes: exact matches, –source organism of epitopes:
InﬂuenzaA virus, –host organismof immunization: human;–qualitative
measurements of B- and T-cell assay: “positive,” “positive-low,” “positive-
intermediate,” or “positive-high”).
To understand availability of conserved epitopes in the population
coverage, information of HLA restriction of conserved epitopes was
collected from the annotation of conserved epitopes in IEDB.
5.3. Alignment, sequence distances and clustering analysis of inﬂuenza
A/H3N2 virus sequences
First, pairwise distances of the protein sequences were calculated
using MEGA4 software [42] (using the Poisson correction model to
measure sequence differences as sequence distances). The MUSCLE
software [43]was used to alignmultiple sequences (using the following
options: -distance1=kbit20_3, -maxiters=1, -diags, -sv, -stable).
Sequence distances were normalized by dividing the number of differ-
ences by the length of the aligned sequences in an alignment.
Next, k-means clustering was performed on the sequence distance
matrix of each viral protein to determine the viral clusters. K-means
clustering is a partitioning method that will partition n input values/
observations into k clusters. In order to determine the appropriate num-
ber of clusters, the function pamk() in the fpc package in R softwarewas
used to obtain the suggested number of clusters based on optimum
average silhouette width.
Finally, consensus sequences as the representative sequences in
each cluster were determined by themajority vote rule. We then calcu-
lated the sequence conservations of epitopes in these representative
sequences.
5.4. Sequence analysis of conservation of epitopes in inﬂuenza A/H3N2
viruses
When performing epitope conservation calculation, we used the
following formula to depict the conservation of the given epitope:
Number of epitopes that are identical to consensus sequences
Number of consensus sequences
 100
5.5. Statistical evaluation of conserved epitopes by cross-validation with
random sampling
Statistical tests were performed to evaluate the signiﬁcance of epi-
tope conservations in training sets and testing sets whichwere selected
by using 5-fold cross-validation with random sampling. 80% of total in-
ﬂuenza sequences were randomly assigned into training sets and the
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PERL package List::Util was used for dividing the sequences into the
training and testing sets.
The “conserved epitope” must meet each of the following require-
ments. The paired sample t-test was used (1) to test whether the
mean of conservation in training set is less than and equal to the conser-
vation in testing set (pb0.05) and (2) to determine whether mean of
conservation in the training set is greater than 99% (pb0.05).
5.6. Calculation of percentages of inﬂuenza A/H3N2 viruses containing
conserved epitopes during the 1968–2010 period
To understandwhether conserved epitopes had existed inwild-type
H3N2 strains, the percentages of the presence of conserved epitopes
were estimated using the following formula:
Number of viral sequences containing identical epitope sequences in a given year
Number of total viral sequences in a given year
 100
5.7. Evaluation of sequence identities of conserved epitopes among
vaccine strains
To evaluate whether the sequences of conserved epitope match to
sequences of various inﬂuenza strains, sequence identities of the con-
served epitopes among inﬂuenza vaccine strains were calculated by
using the BLAST sequence comparison tool [44]. The conserved epitopes
identiﬁed in our results were used as query sequences and sequences
of vaccine strains were available in NCBI (options of ﬁlters: inﬂuenza
A/H3N2 viruses and only vaccine strains) as subject sequences. The
length of the alignmentmust cover the total length of the given epitope.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.ygeno.2012.06.003.
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